The Medicine We Hope Not to Need

A hospital can value a medicine for being there when other options fail. A conventional sales forecast has a harder time putting a number on that readiness.

New antibiotics expose this tension unusually clearly. Developing a useful treatment requires sustained scientific and financial commitment. Once available, an antibiotic needs to be used appropriately, with attention to preserving its effectiveness. A commercial story built around ever-increasing use can pull in a different direction.

The issue invites a broader question about biotechnology: how should a health system reward a capability that matters partly because it is held in reserve?

A pipeline needs more than a count

WHO's June 2024 assessment warned that the antibacterial development pipeline lacked both sufficient candidates and sufficient innovation. It evaluated the pipeline in relation to priority drug-resistant bacteria, looking beyond the mere existence of another program. This is a dated assessment, not a claim that its counts describe today's pipeline.[1]

The distinction between activity and useful progress is crucial. Ten programs are not interchangeable if they address different organisms, resistance patterns, patient populations, or treatment settings. A development portfolio needs an account of the gaps it could fill, alongside an honest view of the risks that remain.

For a reader examining a promising new antibiotic, that suggests a practical opening question: which difficult treatment decision could this product change? The answer should connect the laboratory result to a clinical situation, rather than allowing novelty alone to carry the story.

The quiet shelf can have value

Imagine a fictional health system with access to an antibiotic intended for a defined group of serious infections. During one period it is used infrequently. That low volume could reflect several different realities: careful prescribing, a small eligible population, an access problem, or a product that offers less useful benefit than expected.

This scenario illustrates why sales volume alone cannot tell the whole story. It takes evidence to distinguish successful preparedness from unused inventory. The system would need to understand whether eligible patients could obtain the treatment, whether clinicians knew when to consider it, and whether supply was dependable.

A fire service offers an imperfect but useful analogy. Its value is not assessed only by the number of fires attended. Readiness matters, as does the ability to respond effectively when needed. Medicines still require their own evidence of benefits, risks, and appropriate use; the analogy simply makes room for availability as part of value.

A different way to pay

NHS England's antimicrobial subscription approach provides a concrete example. Its published commercial guidance describes paying a fixed annual fee based on value to the NHS, instead of tying payment to the volume used. This separates the payment principle from the expectation that selling more units is always the route to greater reward.[2]

The idea is appealing because it changes what the arrangement can recognize. Its success still depends on the details: selecting useful products, evaluating their contribution, maintaining access, and ensuring reliable supply. A payment structure cannot substitute for a medicine that works or a system capable of using it well.

For developers, the implication is that the evidence story may need to explain a product's place in preparedness as well as its role in treatment. For payers, it means making assumptions about value explicit enough to review. For patients, the meaningful outcome is simpler: an appropriate option is available when it is needed.

Discovery and restraint belong together

The enduring challenge is to support innovation while keeping appropriate use central. Diagnostics, clinical expertise, supply planning, and prescribing practices all influence what a new antibiotic can accomplish in a particular setting. A discovery reaches its purpose through that surrounding system.

Seen this way, preparedness is a continuing responsibility. A product launch is one milestone. Maintaining the capability to recognize a need, select an appropriate treatment, and deliver it reliably is another.